Esketamine, the active ingredient in Spravato, is a non-selective, non-competitive antagonist of the NMDA receptor, a known ...

The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with ma ...

The US Food and Drug Administration has approved a new nasal spray for depression treatment. Known as Spravato and ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

The FDA has approved esketamine (Spravato) nasal spray as a monotherapy for adults with treatment-resistant depression. This ...

The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first ...

Johnson & Johnson’s (J&J) nasal spray Spravato (esketamine) has received a label expansion, now approved as a monotherapy ...

The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...

The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its ...

The FDA approves Johnson & Johnson's sNDA for Spravato as a monotherapy for adults with treatment-resistant depression.

The FDA has approved Spravato (esketamine) nasal spray for use as monotherapy for patients with treatment-resistant depression.

Titusville: Johnson & Johnson has announced the U.S. Food and Drug Administration (FDA) approval of a supplemental New Drug ...